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Abstract
Dietary cholesterol is a crucial risk factor for nonalcoholic steatohepatitis (NASH). Our 
recent studies indicated that high cholesterol intake was associated with the pathogenesis 
of hypertension-associated NASH. We developed a novel hypertensive rat model of NASH 
by feeding stroke-prone spontaneously hypertensive rats (SHRSP5/Dmcr) a high fat and 
cholesterol (HFC) diet. Histological features resembling human NASH were observed in 
this model. Furthermore, we investigated the kinetics of cholesterol in the rats fed an HFC 
diet and determined that suppression of bile acid (BA) detoxification led by HFC feeding 
results in cytotoxic BA accumulation in hepatocytes, which induces inflammatory response 
and liver damage. Sex differences in fibrogenesis were also observed in this model, and we 
found this was associated with a different ability in BA detoxification. Since SHRSP5/Dmcr 
rats are hypertensive, we investigated the role of hypertension in NASH progression by 
comparing NASH development among SHRSP5/Dmcr rats, spontaneously hypertensive 
rats and their original strain, Wistar Kyoto, with normal blood pressure. HFC diet induced 
more severe hepatic fibrosis in the hypertensive strains compared with the normotensive 
one. In conclusion, dietary cholesterol plays an essential role in the pathogenesis of NASH, 
and the combined action of cholesterol and hypertension further aggravates its progression.
Keywords: cholesterol, hypertension, nonalcoholic steatohepatitis, spontaneously 
hypertensive rat, Wistar Kyoto rat, CYP7A1, kinetics of bile acids, gender differences in 
fibrogenesis
1. Introduction
High dietary cholesterol intake may lead to increased risk of diseases such as cardiovascular 
disease and diabetes [1, 2]. Although the recommendation to restrict daily dietary cholesterol 
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intake (300 mg) was removed from the 2015–2020 Dietary Guidelines for Americans [3], it is 
still recommended that individuals minimize cholesterol consumption. Animal foods such 
as egg yolk, meats, dairy products, fish, and poultry are major sources of dietary cholesterol. 
Meanwhile, dietary cholesterol is not found in plant foods. Instead, many plants contain phy-
tosterols, which are chemically similar to cholesterol, and can therefore compete with it and 
decrease its absorption in the intestinal tract [4]. The effect of dietary cholesterol on plasma 
cholesterol levels remains undetermined, since the body may suppress endogenous choles-
terol synthesis in response to additional cholesterol ingestion [1]. Some studies have sug-
gested that dietary cholesterol increases serum total cholesterol (TC), low-density lipoprotein 
(LDL) cholesterol, as well as the ratio of LDL to high-density lipoprotein cholesterol [5–8], 
which are considered to be associated with risk of vascular diseases.
Dietary cholesterol is also linked to the pathogenesis of nonalcoholic fatty liver disease 
(NAFLD)/nonalcoholic steatohepatitis (NASH) [9, 10]. NAFLD is one of the most common 
chronic liver diseases worldwide and comprises a spectrum of liver damage, from simple 
steatosis (a benign non-progressive condition) to NASH, the advanced form that may prog-
ress to hepatic cirrhosis or hepatocellular carcinoma [11]. The pathological characteristics of 
NASH include steatosis, hepatocellular ballooning, lobular inflammation, and hepatic fibro-
sis. Cholesterol may contribute to NASH development by being catabolized in the liver into 
bile acids (BAs), which are hepatotoxic and cause liver damage [12]. Li et al. demonstrated 
that dietary cholesterol exacerbates liver damage and hepatic inflammation in mice fed a 
high-fat diet [13]. Subramanian et al. reported that an LDL receptor-deficient mouse fed a 
high-fat, high-carbohydrate diet was a good animal model of NAFLD/NASH, and showed 
that dietary cholesterol worsened hepatic steatosis and inflammation in this model [9].
In addition, NAFLD/NASH was described as a hepatic manifestation of metabolic syndrome, 
and its development was associated with hypertension, obesity, diabetes, and hyperlipidemia 
[14, 15]. Some studies have shown an increased prevalence of NAFLD/NASH among hyper-
tensive patients [16–18]. Using spontaneously hypertensive (SHR) rats fed a choline-deficient 
diet as a hypertensive animal model of NASH, and its normotensive control, the Wistar Kyoto 
(WKY) rat [19], Ikuta et al. revealed that hypertension enhances the progression of NASH. We 
previously developed a novel animal model of hypertension-associated NASH by feeding 
stroke-prone spontaneously hypertensive5/Dmcr (SHRSP5/Dmcr) rats a high fat and choles-
terol (HFC) diet [20]. Further studies from our group suggested that dietary cholesterol may 
have a potential effect on the development of hypertension-associated NASH (unpublished).
In this chapter, we will discuss the crucial role of dietary cholesterol in the progression of 
hypertension-associated NASH.
2. The development of a novel animal model of NASH and the 
mechanism underlying the progression of NASH in this model
The mechanisms of the pathogenesis of NASH are not completely understood, partly due 
to a lack of ideal animal models with histological patterns that resemble human NASH. 
Matsuzawa et al. showed that an HFC diet (an atherogenic, high-fat diet containing 1.25% 
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cholesterol and 60% fat) induced steatohepatitis, cellular ballooning, and fibrosis in the livers 
of male C57Bl/6J mice [21]. We previously established an HFC diet-induced NASH model 
using hypertensive SHRSP5/Dmcr rats [20].
SHRSP5/Dmcr rats are the fifth substrain of the stroke-prone spontaneously hypertensive 
(SHRSP) rat [20, 22], which is derived from the SHR strain [23]. To establish this strain, 
SHRSP rats were fed an HFC diet for 1 week, then those with high serum cholesterol levels 
(600–900 mg/dL in females and 300–600 mg/dL in males) were selected for brother–sister 
inbreeding. Selective inbreeding was repeated and offspring with increased hypercholes-
terolemic responses were obtained. Although the SHRSP5/Dmcr rats, formally known as 
arteriolipidosis-prone rats, were developed as an animal model of arteriosclerosis, marked 
enlargement and an abnormal whitish color of the liver were noted in the 47th generation. 
These findings prompted our studies on HFC diet-induced liver damage in this strain.
In order to determine whether the HFC diet-fed SHRSP5/Dmcr strain was a suitable model of 
NASH, we investigated hepatic histopathological changes following HFC feeding [20]. Male 
SHRSP5/Dmcr rats at 10 weeks of age were fed either an HFC (35.3% crude lipid and 5% choles-
terol) or control diet (4.8% crude lipid and no additional cholesterol) for 2, 8, and 14 weeks. We 
found that the HFC diet induced microvesicular steatosis and lymphocyte infiltration at 2 weeks. 
Macrovesicular steatosis, ballooned hepatocytes with eosinophilic Mallory-Denk bodies, and 
multilobular necrosis were observed in the livers of rats fed an HFC diet at 8 weeks. The severity of 
steatosis and hepatocyte ballooning was further increased at 14 weeks. Meanwhile, a progressive 
deterioration of hepatic fibrosis occurred during HFC feeding. Slight pericellular and perivenular 
fibrotic changes, bridging fibrosis, and end-stage honeycomb fibrosis were observed at 2, 8, and 
14 weeks, respectively. In addition, the HFC diet induced a progressive increase in indicators 
of liver damage, including serum levels of alanine transaminase (AST), aspartate transaminase 
(ALT), and γ-glutamyltranspeptidase (γ-GTP). Matteoni et al. classified human NAFLD into four 
types according to histological analysis of liver biopsy specimens: type 1, fatty liver alone; type 2, 
fat accumulation and lobular inflammation; type 3, fat accumulation and ballooning degenera-
tion; and type 4, fat accumulation, ballooning degeneration, and hepatic fibrosis [24]. The histo-
logical characteristics observed in the liver of the SHRSP5/Dmcr strain at 2, 8, and 14 weeks of 
HFC feedings were very similar to those in type 2, type 3 or 4, and type 4 human NAFLD, respec-
tively. Therefore, all pathological stages of NAFLD can be observed in the SHRSP5/Dmcr strain 
during HFC feeding. In addition, obesity, insulin resistance, and diabetes were not observed in 
this model. Therefore, it represents an excellent model of NAFLD/NASH without obesity and 
diabetes, and is useful for studying the pathogenesis and therapeutics of this disease.
We further investigated the molecular mechanisms underlying the progression of HFC-
induced NASH in the SHRSP5/Dmcr strain [25]. Rats were fed either an HFC or control diet 
for 2, 8, and 16 weeks, and expression of genes involved in inflammation and hepatic fibrosis 
was evaluated. Tumor necrosis factor α (TNF-α), a proinflammatory cytokine, was reported to 
be upregulated in the livers of NASH patients [26]. We showed that the HFC diet increased the 
hepatic expression of TNF-α in SHRSP5/Dmcr rats at all time points. Nuclear factor κB (NF-κB; 
p50/p65) and inhibitor of κBα, the proteins involved in NF-κB signaling, which is regulated 
by TNF-α and plays an important role in inflammatory response, were also upregulated by 
the HFC diet. Hepatocyte injury and inflammation led to hepatic fibrosis via hepatic stellate 
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cell (HSC) activation, which results in the production and deposition of extracellular matrix 
(ECM) [27]. The HFC diet induced the upregulation of transforming growth factor-β1 (TGF-
β1), a profibrotic cytokine that promotes HSC activation, prior to the appearance of obvious 
hepatic fibrosis (at 2 weeks). Its upregulation was also observed at subsequent stages (at 8 and 
16 weeks). Expression of alpha smooth muscle actin (α-SMA) and platelet-derived growth fac-
tor-B, involved in hepatic fibrosis, were elevated at 8 weeks of HFC feeding, indicating exten-
sive activation of HSC at this time point. Alpha-1 type I collagen, the major component of ECM, 
was produced by activated HSC (myofibroblast) and was markedly elevated at 8 and 16 weeks, 
corresponding to the appearance of extensive liver fibrosis observed at the same time points.
In order to investigate the role of dietary cholesterol in the pathogenesis of HFC diet-induced 
NASH in SHRSP5/Dmcr rats, we compared hepatic histological changes induced by a high fat 
(HF) diet and those by an HFC diet (unpublished). As described above, the HFC diet induced 
severe steatosis, lymphocyte infiltration, ballooned hepatocytes, and fibrosis in the livers of 
the rats. In contrast, HF feeding only led to mild hepatic steatosis and lymphocyte infiltration, 
while liver fibrosis was not observed. It was suggested that dietary cholesterol may play a key 
role in the transition from simple steatosis to fibrotic steatohepatitis, the progressive stage, 
during the progression of NAFLD/NASH.
3. The role of hypertension in the progression of NASH
SHRSP5/Dmcr rats are hypertensive, making this strain an ideal model in which to study the 
correlation between hypertension and NASH. In our previous study, we investigated the mech-
anism underlying the development of hypertension-associated NASH using three strains of a 
rat: normotensive WKY, hypertensive SHR and SHRSP5/Dmcr [28]. As mentioned previously, 
SHRSP5/Dmcr was established from the SHRSP strain, which was derived from SHR strain that 
was developed from normotensive WKY rats by selective inbreeding of the rats with spontane-
ously high systolic blood pressure in normal conditions [29]. Male rats with a blood pressure 
of 150–175 mmHg persisting for more than 1 month, and females with a blood pressure of 130–
140 mmHg were mated, and the offspring with high blood pressure (over 150 mmHg persist-
ing for more than 1 month) were selected for further inbreeding. The severity of hypertension 
was elevated from generation to generation, and all the rats from the third to sixth generation 
developed spontaneous hypertension by 15 weeks of age. Since the SHR and WKY originated 
from the same parental outbred Wistar rats, the WKY strain was used as the normotensive 
control for the SHR and SHRSP5/Dmcr strains. The blood pressure in the adult male rats of the 
three strains, WKY, SHR, and SHRSP5/Dmcr, were 130, 235, and 180 mmHg, respectively [28].
In our study, the normotensive WKY strain, and two hypertensive SHR and SHRSP5/Dmcr 
strains were fed either the HFC or control diet for 8 weeks. Changes to liver pathology and 
expression of proteins associated with inflammation and oxidative stress were determined [28]. 
We evaluated serum levels of AST, ALT, and γ-GTP, and confirmed that mild liver damage 
occurred in the hypertensive strains in the absence of HFC feeding, suggesting that hyperten-
sion may be a risk factor for chronic liver disease. The HFC diet induced more severe lobular 
inflammation and hepatic fibrosis in the hypertensive strains compared with the normotensive 
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strain. The  severity of the hepatic fibrosis observed in the SHRSP5/Dmcr strain was even higher 
compared with that of the SHR strain. The HFC diet induced elevation of serum inflamma-
tory cytokines, TNF-α and TGF-β1, in the hypertensive strains, whereas an increase in TGF-β1 
was not observed in the normotensive rats. The combination of TNF-α and TGF-β1 may trig-
ger a more severe inflammatory response in the hypertensive rats by regulating the activation 
of downstream inflammatory signaling such as NF-κB and mitogen-activated protein kinase 
(MAPK) pathways. Increased activation of NF-κB and MAPK (p38 and JNK) signaling occurred 
in the hypertensive strains, which may have contributed to the more severe lobular inflamma-
tion observed in these rats. In addition, oxidative stress, defined as an imbalance between the 
production of reactive oxygen species (ROS) and their elimination by antioxidant defenses, 
may lead to cellular injury and chronic inflammation [30]. An increase in oxidative stress in 
NASH patients was previously reported [31, 32]. We measured serum thiobarbituric acid reac-
tive substances levels and found that oxidative stress was significantly elevated in hypertensive 
strains fed an HFC diet but not in normotensive rats (unpublished data). Meanwhile, in hyper-
tensive rats, the HFC diet suppressed the nuclear factor erythroid 2-related factor 2 (Nrf2)/
Kelch-like ECH-associated protein 1 (Keap1) pathway, involved in antioxidative defenses [33]. 
We also found that hepatic levels of superoxide dismutase-1 (SOD-1) [25] and SOD-2 [28], that 
contribute to antioxidant defense by catalyzing the dismutation of superoxide anions [34], were 
decreased in hypertensive SHRSP5/Dmcr rats fed the HFC diet. The decrease in SOD-2 expres-
sion induced by HFC feeding was not observed in normotensive WKY and hypertensive SHR 
strains [28]. This could suggest that an increase in oxidative stress and a lower antioxidative 
capacity may trigger a more severe inflammatory response and liver damage in hypertensive 
rat strains following HFC feeding, compared with normotensive strains.
4. The role of cholesterol in the development of hypertension-
associated NASH
As previously stated, dietary cholesterol intake is considered a risk factor for NAFLD/NASH. The 
liver is a crucial organ implicated in the regulation of cholesterol metabolism, including the 
synthesis and secretion of cholesterol, as well as the synthesis of BAs from cholesterol (a major 
pathway for hepatic cholesterol catabolism) and BA detoxification [35]. Disturbed cholesterol 
homeostasis in the liver is thought to be associated with the pathogenesis of NAFLD/NASH 
[35]. Our study showed that the HFC diet increased serum and hepatic levels of TC in the 
hypertensive SHR and SHRSP5/Dmcr strains, as well as the normotensive WKY strain [28]. It 
is worth noting that the increase in hepatic TC levels in the hypertensive rats was significantly 
lower than those in the normotensive WKY strain. Therefore, we postulated that more choles-
terol was consumed for the synthesis of BAs in the livers of the hypertensive rats. In addition, 
serum TC levels in the hypertensive strains fed the control diet were markedly lower compared 
with those of the normotensive WKY strain, suggesting that the dysregulation of cholesterol 
metabolism may play an important role in the progression of hypertension-associated NASH.
In order to investigate the kinetics of cholesterol during the development of HFC-induced 
NASH in our hypertensive SHRSP5/Dmcr rat model, we evaluated the expression of proteins 
The Role of Cholesterol in the Pathogenesis of Hypertension-Associated Nonalcoholic…
http://dx.doi.org/10.5772/intechopen.76199
113
involved in de novo cholesterol synthesis, cholesterol uptake from bloodstream in the form 
of LDL, cholesterol secretion into blood in the form of very-low-density lipoprotein, and BA 
synthesis and detoxification [36].
4.1. De novo cholesterol synthesis and its uptake from blood
Excessive intake of cholesterol may suppress de novo cholesterol synthesis via a feedback 
mechanism dependent on the transcriptional factor sterol regulator element-binding protein 
2 (SREBP-2) [35]. SREBP-2 resides in the endoplasmic reticulum and remains there when cho-
lesterol is abundant in hepatocytes; however, SREBP-2 is activated in response to low levels of 
cholesterol and translocated to the nucleus, where it triggers the expression of various genes, 
including low-density lipoprotein receptor (LDLR) and 3-hydroxy-3-methylglutaryl coenzyme 
A reductase (HMGCR). HMGCR is the rate-limiting enzyme for cholesterol biosynthesis. Our 
study showed that HMGCR was downregulated in the livers of SHRSP5/Dmcr rats during 
consumption of the HFC diet (2, 8, and 14 weeks), although SREBP-2 expression remained 
unchanged [36]. It was proposed that additional signaling, except SREBP-2, may be required 
for cholesterol synthesis in our rat model. The HFC diet decreased the expression of LDLR and 
LDLR-related protein 1, which are required for clearing cholesterol-contained lipoproteins from 
the blood by the liver [37]. Therefore, excessive intake of dietary cholesterol led to accumulation 
in the liver and consequently resulted in suppression of cholesterol synthesis and uptake.
4.2. BA synthesis and excretion
There are two major pathways of BA synthesis. The classic pathway is initiated by cholesterol 
7 alpha-hydroxylase (CYP7A1), the rate-limiting enzyme, followed by the catalytic action of 
sterol 12 alpha-hydroxylase (CYP8B1) [38]. On the other hand, the initial step in the alterna-
tive (acidic) pathway is catalyzed by sterol 27-hydroxylase (CYP27A1), followed by oxysterol 
7alpha-hydroxylase (CYP7B1). The major primary BAs, cholic acid (CA) and chenodeoxy-
cholic acid (CDCA), are produced from cholesterol in the liver, while the secondary BAs, 
lithocholic acid (LCA) and deoxycholic acid (DCA), are generated from CDCA and CA in the 
intestines, respectively. After synthesis, conjugation of Bas is required for effective transport 
and detoxification [39]. BAs are conjugated with amino acids (taurine or glycine) or sulfate, 
mediated by BA coenzyme A synthase and BA amino acid transferase, and sulfotransferase 
(SULT2A1), respectively. Some BAs are glucuronidated by UDP-glucuronosyl N-transferases 
(UGT1A1, 2B4, and 2B7). Amino acid-conjugated BAs are excreted from the liver into the bile 
canaliculi via the bile salt export pump (BSEP), an ATP-binding cassette (ABC) transporter 
protein located in the canalicular membrane of hepatocytes [40]. Multidrug-resistant protein 
2 (MRP2) is another ABC transporter implicated in the transport of sulfated or glucuronidated 
BAs to bile, while MRP3, located in the basolateral membrane of hepatocyte, is responsible 
for the transport of BAs from the liver to the blood. In addition, bile acid-activated nuclear 
receptors (a group of transcriptional factors), such as farnesoid X receptor (FXR), pregnane 
X receptor (PXR), and constitutive androstane receptor (CAR), are implicated in the regula-
tion of BA metabolism, including synthesis, transport, and detoxification [39]. Several studies 
have reported that activation of FXR, PXR, and CAR inhibits transcription of the CYP7A1 
gene in hepatocytes, and therefore suppress BA synthesis [41–43]. Activation of FXR and PXR 
also induces expression of the BA transporter proteins, BSEP and MRP2 [44–46].
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Increased levels of hepatic BA were observed in NASH patients and were correlated with 
inflammation and fibrosis in the liver [47]. In our SHRSP5/Dmcr model, the HFC diet increased 
hepatic levels of CYP7A1 but decreased levels of CYP8B1, while CYP27A1 was downregulated 
and CYP7B1 was upregulated [36]. We used ultra-performance liquid chromatography–tandem 
mass spectrometry (UPLC-MS/MS) to further determine the hepatic levels of 21 types of BA in 
rats fed the HFC or control diet [48]. The HFC diet significantly increased total BA levels in the 
liver at 2 weeks, but decreased it at 8 weeks. We also investigated the composition of the total 
BA in the rats’ livers. In the total BA pool, the relative proportions of CDCA species, which 
are hydrophobic and show high cytotoxicity [49], were markedly elevated at 8 and 14 weeks, 
whereas hydrophilic CA species, with lower toxicity, were significantly decreased at 14 weeks. 
The ratio of total CA to CDCA was prominently reduced by HFC feeding at 8 and 14 weeks. 
Most BAs (about 90% of the total) in the livers of rats fed the control diet were taurine-conju-
gated. In contrast, glycine-conjugated BAs were predominant in HFC-fed rats. In addition, cana-
licular transporters, BSEP and MRP2, were reduced in the livers of the rats during HFC feeding 
(2, 8, and 14 weeks), whereas MRP3, the basolateral transporter, was significantly increased at 
8 and 14 weeks [36]. Therefore, the accumulation of total BAs in the rats’ liver at 2 weeks of 
HFC feeding may have resulted from suppressed BA excretion to the bile duct, mediated by 
BSEP and MRP2 transporter proteins. Meanwhile, the decrease in total BA levels in the liver at 
8 weeks may have been triggered by an increase in MRP3-mediated BA excretion to the blood. 
Furthermore, we demonstrated that the ratio of CA to CDCA was negatively correlated with 
liver injury (macrovesicular steatosis, serum ALT levels, and fibrotic area), whereas total glycol-
BA/total tauro-BA was positively correlated. Therefore, the accumulation of BAs at 2 weeks of 
HFC-feeding, led by dysregulated BA synthesis and excretion, may trigger liver damage during 
the initial stages of NAFLD/NASH. Furthermore, a decrease in nuclear FXR, PXR, and CAR was 
observed in the livers of rats following HFC feeding. The downregulation of these nuclear recep-
tors may be responsible for the increase in CYP7A1, as well as the decrease in BSEP and MRP2.
4.3. BA detoxification
Toxic BA accumulation in the liver induces hepatocyte injury, and BA hydrophobicity is cor-
related with cytotoxicity [12]. The order of BA hydrophobicity was reported to be CA < CDCA 
< DCA < LCA [12]. Hydrophobic BAs are potent inflammatory agents, whereas the hydrophilic 
BAs are anti-inflammatory [38]. Hydrophobic BAs stimulate ROS generation in hepatic mito-
chondria and lead to oxidative stress, hepatocyte apoptosis, and subsequent liver damage [50, 
51]. BAs with detergent properties may also induce damage in hepatocyte membranes by bind-
ing to membrane components and disrupting the integrity of the plasma membrane [12, 52].
BA metabolism is tightly regulated to prevent the retention of excessive BAs in the liver [12]. 
Sulfation and glucuronidation of BAs, catalyzed by SULT2A1 and UGT, respectively, are 
major detoxification pathways of Bas [53, 54]. These reactions increase the solubility of BAs, 
enhance their fecal and urinary excretion, and reduce their toxicity. In addition, the nuclear 
receptors, PXR and CAR, protect hepatocytes from BA toxicity by regulating the transcription 
of genes involved in BA detoxification, including SULT and UGT [55, 56]. Our study showed 
that the HFC diet impaired BA detoxification by inducing the downregulation of PXR and 
CAR and further suppressing SULT2A1-catalyzed sulfation and UGT-catalyzed glucuronida-
tion in the hypertensive SHRSP5/Dmcr rats [36].
The Role of Cholesterol in the Pathogenesis of Hypertension-Associated Nonalcoholic…
http://dx.doi.org/10.5772/intechopen.76199
115
5. CYP7A1
Our previous study showed that dysregulated expression of enzymes involved in BA synthesis 
led to the accumulation of BA in the livers of SHRSP5/Dmcr rats fed an HFC diet [36]. We fur-
ther investigate the role of CYP7A1 in the pathogenesis of hypertension-associated NASH, and 
evaluated its hepatic levels in hypertensive SHR and SHRSP5/Dmcr rats, and the normotensive 
WKY strain [28]. Constitutive CYP7A1 levels were markedly higher (over 300-fold) in the hyper-
tensive strains compared with those in the normotensive WKY strain. Upregulation of CYP7A1 
may result in an excessive accumulation of toxic BAs, such as hydrophobic BAs, which may lead 
to oxidative stress and liver damage. In addition, Kamisako et al. showed that the Nrf2 pathway 
may regulate the expression of genes associated with BA synthesis and fatty acid metabolism, 
including CYP7A1 [57]. Our study showed increased activation of Nrf2 signaling in the livers of 
hypertensive rats fed a control diet compared with the normotensive WKY, which might be the 
responsible for the overexpression of CYP7A1 in the hypertensive strains [28].
6. Gender differences in NASH development
The prevalence and severity of human NAFLD/NASH varies with gender and age [58]. Yatsuji 
et al. studied 193 Japanese patients with NASH (86 women and 107 men) and showed a predomi-
nance of the disease in women over 50 years old, yet a greater prevalence in men aged 30–40 years 
[59]. Williams et al. reported that NAFLD patients were more likely to be male, older, and hyper-
tensive [60]. The incidence of NAFLD/NASH is higher in men than premenopausal women (less 
than 50 years of age), while this immediately increases in women after menopause. Therefore, 
sex hormones such as estradiol may influence gender differences in NASH. In our study, we 
regarded female SHRSP5/Dmcr rats aged 12–24 weeks to correspond to the menopausal age in 
women. We also found female rats were less susceptible to HFC diet-induced liver damage com-
pared with males [61]. Hence, our rat model may be useful for studies into gender differences in 
HFC-induced NASH. In order to investigate the related mechanisms, mature female and male 
SHRSP5/Dmcr rats (10 weeks old) were fed either an HFC or control diet for 2, 8, and 14 weeks. 
The severity of hepatic fibrosis was markedly lower in the female rats compared with the males. 
Although HFC feeding significantly reduced serum estradiol levels in female rats at 2 weeks, 
these levels were still much higher in females compared with males during HFC feeding, sug-
gesting that this female hormone may contribute to the gender difference in NASH. In addition, 
only minor gender differences were noted in the expression of CYP7A1, CYP8B1, CYP27A1, and 
CYP7B1, the enzymes involved in BA synthesis, as well as MRP3 and BSEP, the proteins associ-
ated with BA transport. On the other hand, the enzymes implicated in BA detoxification, UGT 
and SULT2A1, as well as the nuclear receptors, CAR and PXR, were significantly suppressed in 
the male rats fed the HFC diet, whereas expression of these proteins was only slightly changed 
in females following HFC feeding. Since estradiol, which markedly decreases in women after 
menopause, may stabilize CAR and PXR proteins [61, 62], these results suggested a stronger 
capacity of BA detoxification associated with higher estradiol levels may be responsible for the 
resistance to HFC-induced liver damage and hepatic fibrosis in female rats compared with males.
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7. Treatment of NAFLD/NASH
NAFLD/NASH is related to poor lifestyle, including unhealthy diet habit and lack of exercise, 
which may, in turn, lead to excessive weight gain. Therefore, dietary intervention and exer-
cise, targeted at weight loss, are the primary therapies for obesity-related NAFLD/NASH [63]. 
Vilar-Gomezet al. evaluated the effect of weight loss through lifestyle modifications on the 
improvement of NASH-related histologic features [64]. The study included 293 patients with 
NASH who followed a recommended lifestyle over 52 weeks to reduce body weight, includ-
ing a low-fat, hypocaloric diet (750 kcal per day) and walking (200 min per week). Among 
these patients, 30% lost ≥5% of their weight at 52 weeks, 25% showed resolution of steato-
hepatitis, and 47% showed reduced nonalcoholic fatty liver disease activity score (NAS). This 
study also reported that the extent of weight loss was associated with histologic improve-
ment. A higher proportion of patients with ≥5% weight loss had NASH resolution compared 
with those with ≤5% weight loss. Furthermore, 45% of patients with ≥10% weight loss showed 
regression of hepatic fibrosis.
Although NAFLD/NASH is closely linked with obesity and diabetes, it may also occur in the 
absence of these diseases [65]. As described before, the hypertensive SHRSP5/Dmcr rat repre-
sents a good model of NAFLD/NASH without obesity and diabetes [20]. We used this model 
to investigate the efficacy of dietary intervention for improving HFC-induced NASH [66]. Rats 
were fed an HFC diet for 2 weeks (before the appearance of hepatic fibrosis) or 8 weeks (after 
the appearance of fibrosis), then subsequently fed a control diet for 6 or 12 weeks. We found 
that dietary intervention prior to the appearance of fibrosis markedly improved steatosis and 
suppressed the HFC-induced increase in serum AST, ALT, and TC. On the other hand, dietary 
intervention after the appearance of fibrosis was unable to suppress the increase in serum ALT 
and hepatic TC. Although the dietary intervention (in both cases) reset the increased expres-
sion of fibrosis-relative proteins, TGF-β1 and α-SMA, it only slightly reduced the fibrotic area 
compared with continuous HFC feeding. Taken together, dietary intervention was able to 
completely or partially improve steatosis, inflammation, and cholesterol accumulation in the 
livers of rats fed an HFC diet, although this was not enough to improve hepatic fibrosis.
In addition, several pharmacological agents use in the treatment of NASH, including vita-
min E and pioglitazone, have been tested [67, 68]. Oxidative stress and insulin resistance are 
considered as key factors implicated in the progression of NASH, and are, therefore, attrac-
tive targets for the treatment of NASH [69]. Sanyal et al. tested the efficacy of vitamin E, a 
lipid-soluble antioxidant, and pioglitazone, an insulin sensitizer, in NASH patients without 
diabetes [69]. The 247 patients included in this study received 800 IU vitamin E (84 subjects), 
30 mg pioglitazone (80 subjects), or placebo (83 subjects) daily for 96 weeks. Both vitamin E 
and pioglitazone were associated with improvements in hepatic steatosis and lobular inflam-
mation, as well as a reduction of serum AST and ALT, compared with the placebo. However, 
neither drug had a significant effect on hepatic fibrosis. In conclusion, lifestyle intervention 
(controlled dietary intake as well as exercise) may be the first choice for NAFLD/NASH treat-
ment and should be optimized, while pharmacological management can be used as an auxil-
iary method, and should be further tested in large studies with long-term outcomes.
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Figure 1. Possible mechanism underlying pathogenesis of HFC diet-induced fibrotic steatohepatitis in hypertensive 
SHRSP5/Dmcr rats [25, 35, 47]. In response to cholesterol accumulation in the liver triggered by HFC feeding, 
de novo cholesterol synthesis and its uptake were suppressed, indicated by a reduction in HMGCR, as well as 
LDLR and LPR1. The HFC diet induced dysregulated BA synthesis (upregulated CYP7A1 and CYP7B1, as well 
as downregulated CYP8B1 and CYP27A1) and export (downregulated BSEP and MRP2, as well as upregulated 
MRP3), and led to BA accumulation in hepatocytes. In addition, the HFC diet suppressed BA detoxification by 
decreasing the expression of nuclear receptors (PXR and CAR), and further downregulating SULT2A1 and 
UGT1A1, BA detoxification enzymes. Furthermore, cytotoxic BA accumulation in hepatocytes-induced oxidative 
stress, which activated inflammatory signaling (TNF-α, TGF-β/NF-κB, MAPK) and resulted in hepatitis. Hepatic 
inflammation-induced upregulation of fibrosis-related genes (α-SMA, PDGF-β, Col1a1) and led to hepatic fibrosis. 
Additionally, hypertension enhanced the deterioration of HFC-induced fibrotic steatohepatitis by upregulating 
CYP7A1, further leading to BA accumulation in hepatocytes and increased oxidative stress. On the other hand, 
hypertension induced the suppression of anti-oxidative signaling (Nrf-2/Keap1) following HFC feeding. Therefore, 
elevated oxidative stress and suppressed anti-oxidative capacity triggered a more severe inflammatory response 
in the hypertensive rats fed an HFC diet, as indicated by increased activation of inflammatory signaling (TNF-α, 
TGF-β/NF-κB, MAPK). BA, bile acid; HMGCR, 3-hydroxy 3-methyl-glutaryl-coenzyme A reductase; LDLR, low 
density lipoprotein receptor; LRP1, LDLR-related protein 1; CYP7A1, cholesterol 7α-hydroxylase; CYP8B1, sterol 
12α-hydroxylase; CYP27A1, sterol 27-hydroxylase; CYP7B1, oxysterol 7α-hydroxylase; BSEP, bile salt export pump; 
MRP2, multidrug resistance-associated protein 2; MRP3, multidrug resistance-associated protein 3; FXR, farnesoid X 
receptor; PXR, pregnane X receptor; CAR, constitutive adrostane receptor; SULT2A1, sulfotransferase 2A1; UGT1A1, 
UDP-glucoronosyltransferase 1A1; TNF-α, tumor necrosis factor-α; TGF-β, transforming growth factor; NF-κB, 
nuclear factor kappa B; MAPK, mitogen-activated protein kinase; α-SMA, α-smooth muscle actin; PDGF-B, platelet-
derived growth factor subunit B; Col1a1, alpha 1 type 1 collagen; Nrf-2, nuclear factor erythroid 2-related factor 2; 
Keap1, Kelch-like ECH-associated protein 1.
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8. Conclusions
In our previous study, we established a novel model of fibrotic steatohepatitis by feeding hyper-
tensive SHRSP5/Dmcr rats an HFC diet. Histological features resembling human NASH were 
observed in the rats, suggesting that this model is useful for studying hypertension-associated 
NASH. We compared NASH development among hypertensive strains (SHRSP5/Dmcr and 
SHR) and the normotensive WKY strain, and showed that hypertension accelerates progression 
of HFC-induced NASH by elevating BA synthesis (CYP7A1), inducing increased activation of 
inflammatory signaling (MAPK and NF-κB), and suppressing signaling associated with anti-
oxidant defense (Nrf2/Keap1). To elucidate the role of cholesterol in NASH development, we 
investigated the kinetics of cholesterol in this model, and found that the HFC diet induced dys-
regulation of BA synthesis and suppression of BA detoxification, therefore resulting in cytotoxic 
BA accumulation in hepatocytes, which further induced oxidative stress, followed by activation 
of signaling involved in hepatic inflammation and fibrosis (Figure 1). Sex differences in fibrogen-
esis were also observed in this model and were associated with a different sensitivity to BA tox-
icity. More sustained expression of nuclear receptors, CAR and PXR, and the enzymes involved 
in BA detoxification, UGT and SULT, contributed to the stronger resistance to HFC-induced 
liver damage in female rats compared with males. In conclusion, our studies demonstrate that 
dietary cholesterol may play a crucial role in the progression of NASH-associated hypertension 
and provide a basis for NAFLD/NASH treatment involving restriction of cholesterol intake.
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